Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 2Phase 2 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 8Pain 7Cancer Pain 3Pancreatic Neoplasms 2Breast Neoplasms 2Breakthrough Pain 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thymoma 1Thrombocythemia, Essential 1Testicular Neoplasms 1Stomach Neoplasms 1Standard Opioid Analgesic Treatment of Cancer-related Chronic Pain. 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma 1Salivary Gland Neoplasms 1Respiratory Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Fentanyl 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Breakthrough Pain × Fentanyl × Clear all
NCT00263575 2024-06-18

Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients

Kyowa Kirin Co., Ltd.

Phase 3 Completed
139 enrolled 7 charts

Neoplasms, Pain, Breakthrough Pain

NCT00236145 2013-01-29

Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Completed

Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡